Real-world progression-free survival of patients on anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) for ALK+ non-small cell lung cancer (NSCLC)
Year: 2018
Type: article
Study design: Observational Study
Abstract: Background: Patients with NSCLC characterized by ALK rearrangements may benefit from ALK TKI therapies. Although ALK TKIs have shown improved efficacy relative to conventional chemotherapy, the prognosis for patients with ALK+ NSCLC remains suboptimal. The present study uses real-world evidence to examine progression-free survival (PFS) among patients with ALK+ NSCLC treated with an ALK TKI.
Source: Annals of Oncology
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,080
OpenAlex ID: W2898318338